A multicenter study of the impella device for mechanical support of the systemic circulation in pediatric and adolescent patients

V. Vivian Dimas, Brian H. Morray, Dennis W. Kim, Christopher S D Almond, Shabana Shahanavaz, Sebastian C. Tume, Lynn F. Peng, Doff B. Mcelhinney, Henri Justino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: The objective was to review the use of Impella devices (Abiomed Inc, Danvers, MA) for temporary circulatory support in pediatric and adolescent patients (age≤21 yrs). Background: Options for minimally invasive circulatory support in children are limited, and published data are confined to case reports and small case series. Methods: This was a retrospective, multicenter review of Impella implants in pediatric and adolescent patients from 2009-15, using standardized data collection and INTERMACS definitions. Results: A total of 39 implants were performed in 38 patients from 16 centers. Median age and weight were 16 yrs (4-21 yrs) and 62 kg (15-134 kg). The primary indication for implant was cardiogenic shock in 28 patients (72%). Cardiac allograft rejection, myocarditis, or cardiomyopathy were the underlying diagnosis in 23 patients (59%); 11 patients had congenital heart disease. The median duration of support was 45 hr (1-1224 hr). Indications for explant included ventricular recovery in 16 patients, transition to another device in 12, death in 5, and transplant in 1. Survival was 85% at 7 days and 68% at 30 days. Major adverse events occurred in 8 patients: hemolysis in 3, bleeding in 2, stroke in 1 (unclear if related to Impella), sepsis in 1, and critical leg ischemia in 1. An increase in aortic regurgitation was noted in three patients, with no evidence of valve injury. Conclusion: Temporary circulatory support with Impella devices is feasible in pediatric and adolescent patients, with acceptable risk profiles. More experience and follow up is needed to improve technical performance and patient selection.

Original languageEnglish (US)
JournalCatheterization and Cardiovascular Interventions
DOIs
StateAccepted/In press - 2017

Fingerprint

Multicenter Studies
Pediatrics
Equipment and Supplies
Patient Transfer
Aortic Valve Insufficiency
Cardiogenic Shock
Myocarditis
Hemolysis
Cardiomyopathies
Patient Selection
Allografts
Heart Diseases
Leg
Sepsis
Ischemia
Stroke
Hemorrhage
Transplants
Weights and Measures
Survival

Keywords

  • Congenital heart disease
  • Mechanical support
  • Pediatrics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

A multicenter study of the impella device for mechanical support of the systemic circulation in pediatric and adolescent patients. / Dimas, V. Vivian; Morray, Brian H.; Kim, Dennis W.; Almond, Christopher S D; Shahanavaz, Shabana; Tume, Sebastian C.; Peng, Lynn F.; Mcelhinney, Doff B.; Justino, Henri.

In: Catheterization and Cardiovascular Interventions, 2017.

Research output: Contribution to journalArticle

Dimas, V. Vivian ; Morray, Brian H. ; Kim, Dennis W. ; Almond, Christopher S D ; Shahanavaz, Shabana ; Tume, Sebastian C. ; Peng, Lynn F. ; Mcelhinney, Doff B. ; Justino, Henri. / A multicenter study of the impella device for mechanical support of the systemic circulation in pediatric and adolescent patients. In: Catheterization and Cardiovascular Interventions. 2017.
@article{531530f548294d6aadcf97b8df521f7b,
title = "A multicenter study of the impella device for mechanical support of the systemic circulation in pediatric and adolescent patients",
abstract = "Objectives: The objective was to review the use of Impella devices (Abiomed Inc, Danvers, MA) for temporary circulatory support in pediatric and adolescent patients (age≤21 yrs). Background: Options for minimally invasive circulatory support in children are limited, and published data are confined to case reports and small case series. Methods: This was a retrospective, multicenter review of Impella implants in pediatric and adolescent patients from 2009-15, using standardized data collection and INTERMACS definitions. Results: A total of 39 implants were performed in 38 patients from 16 centers. Median age and weight were 16 yrs (4-21 yrs) and 62 kg (15-134 kg). The primary indication for implant was cardiogenic shock in 28 patients (72{\%}). Cardiac allograft rejection, myocarditis, or cardiomyopathy were the underlying diagnosis in 23 patients (59{\%}); 11 patients had congenital heart disease. The median duration of support was 45 hr (1-1224 hr). Indications for explant included ventricular recovery in 16 patients, transition to another device in 12, death in 5, and transplant in 1. Survival was 85{\%} at 7 days and 68{\%} at 30 days. Major adverse events occurred in 8 patients: hemolysis in 3, bleeding in 2, stroke in 1 (unclear if related to Impella), sepsis in 1, and critical leg ischemia in 1. An increase in aortic regurgitation was noted in three patients, with no evidence of valve injury. Conclusion: Temporary circulatory support with Impella devices is feasible in pediatric and adolescent patients, with acceptable risk profiles. More experience and follow up is needed to improve technical performance and patient selection.",
keywords = "Congenital heart disease, Mechanical support, Pediatrics",
author = "Dimas, {V. Vivian} and Morray, {Brian H.} and Kim, {Dennis W.} and Almond, {Christopher S D} and Shabana Shahanavaz and Tume, {Sebastian C.} and Peng, {Lynn F.} and Mcelhinney, {Doff B.} and Henri Justino",
year = "2017",
doi = "10.1002/ccd.26973",
language = "English (US)",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - A multicenter study of the impella device for mechanical support of the systemic circulation in pediatric and adolescent patients

AU - Dimas, V. Vivian

AU - Morray, Brian H.

AU - Kim, Dennis W.

AU - Almond, Christopher S D

AU - Shahanavaz, Shabana

AU - Tume, Sebastian C.

AU - Peng, Lynn F.

AU - Mcelhinney, Doff B.

AU - Justino, Henri

PY - 2017

Y1 - 2017

N2 - Objectives: The objective was to review the use of Impella devices (Abiomed Inc, Danvers, MA) for temporary circulatory support in pediatric and adolescent patients (age≤21 yrs). Background: Options for minimally invasive circulatory support in children are limited, and published data are confined to case reports and small case series. Methods: This was a retrospective, multicenter review of Impella implants in pediatric and adolescent patients from 2009-15, using standardized data collection and INTERMACS definitions. Results: A total of 39 implants were performed in 38 patients from 16 centers. Median age and weight were 16 yrs (4-21 yrs) and 62 kg (15-134 kg). The primary indication for implant was cardiogenic shock in 28 patients (72%). Cardiac allograft rejection, myocarditis, or cardiomyopathy were the underlying diagnosis in 23 patients (59%); 11 patients had congenital heart disease. The median duration of support was 45 hr (1-1224 hr). Indications for explant included ventricular recovery in 16 patients, transition to another device in 12, death in 5, and transplant in 1. Survival was 85% at 7 days and 68% at 30 days. Major adverse events occurred in 8 patients: hemolysis in 3, bleeding in 2, stroke in 1 (unclear if related to Impella), sepsis in 1, and critical leg ischemia in 1. An increase in aortic regurgitation was noted in three patients, with no evidence of valve injury. Conclusion: Temporary circulatory support with Impella devices is feasible in pediatric and adolescent patients, with acceptable risk profiles. More experience and follow up is needed to improve technical performance and patient selection.

AB - Objectives: The objective was to review the use of Impella devices (Abiomed Inc, Danvers, MA) for temporary circulatory support in pediatric and adolescent patients (age≤21 yrs). Background: Options for minimally invasive circulatory support in children are limited, and published data are confined to case reports and small case series. Methods: This was a retrospective, multicenter review of Impella implants in pediatric and adolescent patients from 2009-15, using standardized data collection and INTERMACS definitions. Results: A total of 39 implants were performed in 38 patients from 16 centers. Median age and weight were 16 yrs (4-21 yrs) and 62 kg (15-134 kg). The primary indication for implant was cardiogenic shock in 28 patients (72%). Cardiac allograft rejection, myocarditis, or cardiomyopathy were the underlying diagnosis in 23 patients (59%); 11 patients had congenital heart disease. The median duration of support was 45 hr (1-1224 hr). Indications for explant included ventricular recovery in 16 patients, transition to another device in 12, death in 5, and transplant in 1. Survival was 85% at 7 days and 68% at 30 days. Major adverse events occurred in 8 patients: hemolysis in 3, bleeding in 2, stroke in 1 (unclear if related to Impella), sepsis in 1, and critical leg ischemia in 1. An increase in aortic regurgitation was noted in three patients, with no evidence of valve injury. Conclusion: Temporary circulatory support with Impella devices is feasible in pediatric and adolescent patients, with acceptable risk profiles. More experience and follow up is needed to improve technical performance and patient selection.

KW - Congenital heart disease

KW - Mechanical support

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=85015185875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015185875&partnerID=8YFLogxK

U2 - 10.1002/ccd.26973

DO - 10.1002/ccd.26973

M3 - Article

C2 - 28295963

AN - SCOPUS:85015185875

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

ER -